GLOBUS MEDICAL INC (GMED) research
GLOBUS MEDICAL INC- Sector
- Healthcare
- Industry
- Medical Devices
- Last price
- $75.60
- As of
GLOBUS MEDICAL INC (GMED): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-06.
As of . Source: SEC EDGAR filings for GMED. Method and limitations.
Share the GMED intelligence card
See the full GMED dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for GMED on one page. Preview it with sample data, then open it live with a free account.
Preview the GMED dossierActive signals for GMED
- highCONSENSUS_SELL
3 tracked funds reduced GMED this 2026Q2, institutional consensus
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 98% of GMED (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 80% of GMED (2026Q2)
- highINSTITUTIONAL_EXIT
D. E. Shaw & Co., Inc. cut 71% of GMED (2026Q2)
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 19.5%, EPS $1.34 vs $1.1213 estimate
FREE, NO ACCOUNT
Every signal on GMED, as it fires
You are seeing 5 of 11 signals recorded on GMED since 2026-05-31.
The five above landed across 2 days. The other 6 were recorded on 2 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in GMED (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| Bridgewater Associates, LPCUSIP 379577208 · 2026Q2 | $27.8M | 0.11% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 379577208 · 2026Q2 | $15.6M | 0.02% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 379577208 · 2026Q2 | $2.3M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 379577208 · 2026Q2 | $656K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, GMED
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
GMED against its peers
GMED's operating margin of 16.3% ranks in the 93rd percentile of 21 Medical Devices sub-industry peers, fiscal periods ending between 2025-12-28 and 2026-05-31.
| Metric | GMED | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 2.9B USD | 303M USD | 93 | 20 |
| Gross margin | n/a | 59.8% | n/a | 19 |
| Operating margin | 16.3% | -11.1% | 93 | 21 |
| Net margin | 18.3% | -9.4% | 84 | 21 |
| Return on equity | 11.8% | -10.6% | 80 | 21 |
| P / E | 19.3x | 34.4x | 25 | 5 |
Peers (21): BIO, SNN, PHG, NEOG, AXGN, BFLY, UFPT, ESTA, IART, AVNS, AORT, ENOV, BBNX, CBLL, SIBN, INMD, QDEL, SSII, KIDS, DCTH, MASS. Left out: ALMR (no annual filing), OSSUY (no annual filing), NHNKF (no annual filing), LMRI (no annual filing). Fiscal periods ending between 2025-12-28 and 2026-05-31. Every figure is one full fiscal year read from one annual filing (GMED: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more GMED signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to GMEDand get the insider, 13F, options, and confluence read in one view.